John Turnidge

List of Publications by Year
in descending order

29 papers	804 citations	758635 12 h-index	610482 24 g-index
29 all docs	29 docs citations	29 times ranked	1116 citing authors

#	Article	IF	Citations
1	MIC-based dose adjustment: facts and fables. Journal of Antimicrobial Chemotherapy, 2018, 73, 564-568.	1.3	233
2	Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clinical Infectious Diseases, 2020, 71, e523-e529.	2.9	94
3	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	2.9	85
4	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. Journal of Antimicrobial Chemotherapy, 2018, 73, 2374-2379.	1.3	65
5	Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Journal of Clinical Microbiology, 2022, 60, JCM0027621.	1.8	56
6	Efflux Pump-Driven Antibiotic and Biocide Cross-Resistance in Pseudomonas aeruginosa Isolated from Different Ecological Niches: A Case Study in the Development of Multidrug Resistance in Environmental Hotspots. Microorganisms, 2020, 8, 1647.	1.6	52
7	Predictability of Phenotype in Relation to Common Î²-Lactam Resistance Mechanisms in Escherichia coli and Klebsiella pneumoniae. Journal of Clinical Microbiology, 2016, 54, 1243-1250.	1.8	38
8	Precision of Vancomycin and Daptomycin MICs for Methicillin-Resistant Staphylococcus aureus and Effect of Subculture and Storage. Journal of Clinical Microbiology, 2014, 52, 3898-3905.	1.8	26
9	Antimicrobial susceptibility testing for bovine respiratory disease: Getting more from diagnostic results. Veterinary Journal, 2015, 203, 149-154.	0.6	26
10	How to: ECOFFsâ€"the why, the how, and the don'ts of EUCAST epidemiological cutoff values. Clinical Microbiology and Infection, 2022, 28, 952-954.	2.8	26
11	Inactivation, removal, and regrowth potential of opportunistic pathogens and antimicrobial resistance genes in recycled water systems. Water Research, 2021, 201, 117324.	5.3	17
12	What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?. Clinical Microbiology and Infection, 2020, 26, 1453-1455.	2.8	14
13	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. Antimicrobial Agents and Chemotherapy, 2021, 65, e0109321.	1.4	12
14	Robotic Antimicrobial Susceptibility Platform (RASP): a next-generation approach to One Health surveillance of antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2021, 76, 1800-1807.	1.3	11
15	MIC-based dose adjustment: facts and fablesâ€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2018, 73, 2585-2586.	1.3	10
16	Comparative macrolide use in humans and animals: should macrolides be moved off the World Health Organisationâ€™s critically important antimicrobial list?. Journal of Antimicrobial Chemotherapy, 2021, 76, 1955-1961.	1.3	8
17	Polymyxin Susceptibility Testing and Breakpoint Setting. Advances in Experimental Medicine and Biology, 2019, 1145, 117-132.	0.8	7
18	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precisionâ€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2019, 74, 1761-1762.	1.3	7

#	Article	IF	Citations
19	Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 1949-1950.	1.3	4
20	EUCAST breakpoint categories and the revised â€œIâ€• a stewardship opportunity for â€œIâ€mproving outcomes. Clinical Microbiology and Infection, 2022, 28, 475-476.	2.8	4
21	Worldwide distribution and environmental origin of the Adelaide imipenemase (AIM-1), a potent carbapenemase in Pseudomonas aeruginosa. Microbial Genomics, 2021, 7, .	1.0	3
22	Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patients. Australian Health Review, 2020, 44, 263.	0.5	2
23	Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study. JAC-Antimicrobial Resistance, 2020, 2, dlaa023.	0.9	2
24	Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective. International Journal of Technology Assessment in Health Care, 2021, 37, e28.	0.2	1
25	â€˜How To: ECOFFs â€“ The why, the how and the don'ts of EUCAST epidemiological cutoff values' â€“ Author's response. Clinical Microbiology and Infection, 2022, 28, 1030-1031.	2.8	1
26	Estimating the utilisation of unregistered antimicrobials in Australia. Infection, Disease and Health, 2020, 25, 82-91.	0.5	0
27	The publication of studies involving the use of human critically important antimicrobial agents in veterinary species. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 986-989.	0.6	0
28	The publication of studies involving the use of human critically important antimicrobial agents in veterinary species: Reply from the authors. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 994-995.	0.6	0
29	Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. Clinical Microbiology and Infection, 2022, , .	2.8	0